David Kirn

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Emeryville, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Scott Bizily as Attorney-in-Fact for David Kirn
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David Kirn

Form 4 holding President and Chief Executive Officer, Director

4D Molecular Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
217,500
Estimated value
Report date
19 Aug 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by David Kirn

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .